본문 바로가기

Long-term macrolide treatment for non-cystic fibrosis bronchiectasis in children: a meta-analysis

문서 유형
연구출판물 · 학술지 논문
등재
SCIEScopus
저널 순위
JCR Q1Scopus Q1
저널
SCIENTIFIC REPORTS11(1) · #24287 · 2021
피인용
Web of Science 13Scopus 16
FWCI (Scopus)
0.46
JCR IF
JCR 2020 4.38
ISSN
2045-2322

저자

  1. Lee, Eun제1저자Chonnam Natl Univ, Chonnam Natl Univ Hosp, Dept Pediat, Sch Med, Gwangju, South Korea
  2. Sol, In SukSungkyunkwan Univ, Kangbuk Samsung Hosp, Dept Pediat, Sch Med, Seoul, South Korea
  3. Kim, Jong DeokYonsei Univ, Severance Hosp, Dept Pediat, Coll Med, Seoul, South Korea
  4. Yang, Hyeon-JongSoonchunhyang Univ, Seoul Hosp, Dept Pediat, Pediat Allergy & Resp Ctr,Coll Med, Seoul, South Korea
  5. Min, Taek KiSoonchunhyang Univ, Seoul Hosp, Dept Pediat, Pediat Allergy & Resp Ctr,Coll Med, Seoul, South Korea
  6. Jang, Gwang CheonIlsan Hosp, Dept Pediat, Natl Hlth Insurance Serv, Ilsan, South Korea
  7. Hwang, Yoon HaBusan St Marys Hosp, Dept Pediat, Busan, South Korea
  8. Cho, Hyun-JuCatholic Kwandong Univ, Int St Marys Hosp, Dept Pediat, Incheon, South Korea
  9. Suh, Dong InSeoul Natl Univ, Dept Pediat, Coll Med, Seoul, South Korea
  10. Kim, KyunghoonCatholic Univ Korea, Dept Pediat, Coll Med, Seoul, South Korea
  11. Kim, Hwan SooCatholic Univ Korea, Dept Pediat, Coll Med, Seoul, South Korea
  12. Kim, Yoon HeeYonsei Univ, Dept Pediat, Coll Med, Seoul, South Korea
  13. Woo, Sung IlChungbuk Natl Univ, Chungbuk Natl Univ Hosp, Dept Pediat, Coll Med, Cheongju, South Korea
  14. Lee, Yong JuYonsei Univ, Yongin Severance Hosp, Dept Pediat, Coll Med, Yongin, South Korea
  15. 정성수Pusan Natl Univ, Childrens Hosp, Dept Pediat, Sch Med, Yangsan, South Korea
  16. Jeon, You Hoon교신저자Hallym Univ, Dept Pediat, Dongtan Sacred Heart Hosp, 7 Keunjaebong Gil, Hwaseong Si 18450, Gyeonggi Do, South Korea

초록

Recurrent bacterial infection causes frequent bronchiectasis (BE) exacerbations. The effectiveness and safety of long-term administration of macrolides in BE remain controversial, especially in children who require minimal treatment to prevent exacerbation. We conducted this meta-analysis to determine the usefulness of long-term macrolide use in pediatric BE. We searched PubMed, Cochrane Library databases, Embase, KoreaMed, Igaku Chuo Zasshi, and Chinese National Knowledge Infrastructure databases. We identified randomized controlled trials (RCTs) which elucidated long-term macrolide treatment (>= 4 weeks) in non-cystic fibrosis BE in children aged < 18 years. The primary outcome was frequency of acute exacerbation; secondary outcomes included changes in pulmonary function, sputum scores, and adverse events including bacterial resistance. We included four RCTs. Long-term macrolide treatment showed a significant decrease in the frequency of exacerbation (odds ratio [OR], 0.30; 95% confidence interval [CI], 0.10-0.87), mean number of exacerbations per patient (mean difference, - 1.40; 95% CI, - 2.26 to - 0.54), and sputum purulence score (mean difference, - 0.78; 95% CI, - 1.32 to - 0.24). However, long-term macrolide treatment was accompanied by an increased carriage of azithromycin-resistant bacteria (OR, 7.13). Long-term macrolide administration prevents exacerbation of BE in children; however, there are risks of increasing antibiotic resistance. Benefits and risks should be weighed and determined on a patient-by-patient basis.

키워드

DOUBLE-BLINDAZITHROMYCINMULTICENTER

식별자

Scopus EID
2-s2.0-85121507224
WoS UID
000733281900013